Medline supporting Trajan pathology in the UK
Trajan Scientific and Medical (Trajan) is pleased to welcome Medline Scientific (Medline) as distributor of its pathology microscopy products in the UK.
Established in 1992 and headquartered in the UK, Medline is a leading supplier across clinical, university, pharmaceutical, food research and industrial laboratory sectors.
Medline extend's Trajan's presence across the UK, offering additional expertise to assist laboratory personnel in selecting slides for optimal tissue adhesion in a wide range of pathologies.
View information about Trajan's pathology range on our website, or purchase microscope slides and coverslips via Medline.
More information
Trajan Scientific and Medical
europe@trajanscimed.com
+44 (0) 1908 568 844
Medline Scientific
enquiries@medlinescientific.com
+44 (0)1865 400321
Media contact information
Trajan Scientific and Medical
media@trajanscimed.com
+44 (0) 1244 403 100
 is pleased to welcome Medline Scientific (Medline) as distributor of its pathology microscopy products in the UK.
Established in 1992 and headquartered in the UK, Medline is a leading supplier acros...&media=//cdn.shopify.com/s/files/1/0767/9441/articles/Frosted_Slides_0195_600x.jpg?v=1477917322){kind=link}
Also in News
Advantages of hemaPEN blood microsampling validated for therapeutic drug monitoring in RSC’s Analyst
Trajan Scientific and Medical’s hemaPEN® has been independently evaluated and the results of the study published in the Royal Society of Chemistry’s journal Analyst - selected for the cover of issue 17. hemaPEN demonstrated significant advantages for blood sampling to support better healthcare decision making.
European patent for Trajan’s hemaPEN
US FDA listing of Trajan’s hemaPEN blood microsampling device
Trajan Scientific and Medical has listed its hemaPEN® blood microsampling device with the U.S. Food and Drug Administration as Class I for therapeutic and in vitro diagnostic use. This follows the hemaPEN’s recent registration in May for supply in the EU and UK as a General IVD; as well as inclusion in the TGA’s ARTG (Australian Register of Therapeutic Goods) in February as a Class I IVD.